Abstract

BackgroundVascular invasion in patients with hepatocellular carcinoma (HCC) is representative of advanced disease with an extremely poor prognosis. The detailed course of its development has not been fully elucidated.MethodsWe enrolled 1057 consecutive patients with HCC who had been treated with curative intent by radiofrequency ablation (RFA) as an initial therapy from 1999 to 2008 at our department. We analyzed the incidence rate of and predictive factors for vascular invasion. The survival rate after detection of vascular invasion was also analyzed.ResultsDuring a mean follow-up period of 4.5 years, 6075 nodules including primary and recurrent lesions were treated by RFA. Vascular invasion was observed in 97 patients. The rate of vascular invasion associated with site of original RFA procedure was 0.66% on a nodule basis. The incidence rates of vascular invasion on a patient basis at 1, 3, and 5 years were 1.1%, 5.9%, and 10.4%, respectively. Univariate analysis revealed that tumor size, tumor number, alpha-fetoprotein (AFP), des-gamma-carboxy prothrombin (DCP), and Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein were significant risk predictors of vascular invasion. In multivariate analysis, DCP was the most significant predictor for vascular invasion (compared with a DCP of ≤100 mAu/mL, the hazard ratio was 1.95 when DCP was 101–200 mAu/mL and 3.22 when DCP was >200 mAu/mL). The median survival time after development of vascular invasion was only 6 months.ConclusionVascular invasion occurs during the clinical course of patients initially treated with curative intent. High-risk patients may be identified using tumor markers.

Highlights

  • Hepatocellular carcinoma (HCC) is a leading cause of cancer death

  • Vascular invasion was observed in 97 patients, developing adjacent and apart from the ablated area in 40 and 57 patients, respectively (Fig. 1)

  • This study showed that vascular invasion occurred in 10% of patients within 5 years when hepatocellular carcinoma (HCC) was initially diagnosed at an early stage

Read more

Summary

Introduction

Hepatocellular carcinoma (HCC) is a leading cause of cancer death. It has a high incidence in Asian countries, including Japan [1,2]. To control this disease, close surveillance using advanced diagnostic modalities including ultrasonography (US), computed tomography (CT), and gadolinium-ethoxybenzyldiethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging (EOB-MRI) in designated high-risk patients has facilitated HCC detection at a very early stage at which surgical resection, liver transplantation, and percutaneous ablative therapies are feasible [3]. Liver transplantation can treat both cancer and liver dysfunction; it has shown excellent survival rates in patients with early stage HCC [5]. The detailed course of its development has not been fully elucidated

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.